<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9057">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989025</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0029</org_study_id>
    <nct_id>NCT02989025</nct_id>
  </id_info>
  <brief_title>Progesterone to Enhance the Safety and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>Progesterone to Enhance the Safety and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia-The PROGRESS Randomized Prospective Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Babbette Lamarca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if giving 17-hydroxyporgesterone caproate (17 OHPC) to
      mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OBGYN house and attending staff on duty caring for the patient will determine
      appropriateness for study inclusion. Once enrolled with informed consent, the participant
      will be randomized by the assigned Coordinator to receive 17 OHPC, 250mg IM or equivalent of
      placebo to be given at admission and every 7 days thereafter. Blood sampling of
      approximately 1-2 teaspoons each will be collected at baseline immediately prior to
      administration of 17 OHPC or placebo, then 24 hours (+-2hrs). After the first 24 hours,
      blood samples will be collected every 72 hrs until delivery and again 24hrs (+- 2hrs) after
      delivery. Placentas will be collected at delivery and the investigators will also collect
      information of the mother and newborn while in the hospital and until discharge including
      de-identified routine ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of maternal and perinatal outcomes</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessment of maternal BP trends</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change is being assessed in Maternal Outcomes</measure>
    <time_frame>12 hours</time_frame>
    <description>Assessment of maternal BP trends</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change is being assessed in Maternal Outcomes</measure>
    <time_frame>48 hours</time_frame>
    <description>Assessment of maternal BP trends</description>
  </other_outcome>
  <other_outcome>
    <measure>Change is being assessed in Maternal Outcomes</measure>
    <time_frame>Until delivery</time_frame>
    <description>Assessment of maternal BP trends</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Placental Abruption</measure>
    <time_frame>Baseline until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Pulmonary edema</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Acute Kidney Injury</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of DIC</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of neurological events</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of laboratory results</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Biomarkers</measure>
    <time_frame>Change from Baseline until delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Infant Weight</measure>
    <time_frame>Delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of APGAR score</measure>
    <time_frame>Delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of NICU stays</measure>
    <time_frame>Delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Interventricular hemorrhage</measure>
    <time_frame>Delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Respiratory Distress Syndrome</measure>
    <time_frame>Delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Necrotizing enterocolitis (NEC)</measure>
    <time_frame>Delivery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal pregnant patient between 23 0/7ths and 34 0/7ths weeks gestation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 OHPC</intervention_name>
    <description>The study participant will be randomized to receive 17 OHPC, 250mg IM or equivalent of placebo will be given at admission and every 7 days thereafter.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Makena, AMAG Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control/Normal Saline</intervention_name>
    <description>The study participant will be randomized to receive 17 OHPC, 250mg IM or equivalent of placebo will be given at admission and every 7 days thereafter.</description>
    <arm_group_label>Control/Normal Saline</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  UMMC antepartum patients with preterm PE between 23 0/7ths and 33 0/7ths weeks
             gestation when initially evaluated

          -  Willing and able to understand study procedures and to provide informed consent

        Exclusion Criteria:

          -  &gt;33 weeks gestational age or &lt;23 weeks gestation

          -  Maternal compromise requiring emergent delivery (ongoing placental abruption, DIC,
             pulmonary edema).

          -  Fetal compromise requiring emergent delivery (fetal bradycardia, recurrent late fetal
             heart rate decelerations, minimal to absent fetal heart rate variability).

          -  Parameters according to current practice guidelines that exclude a patient from
             expectant management include the following:

          -  Preterm premature rupture of membranes (PPROM) &gt; 34 weeks gestation;

          -  Platelet count &lt; 100,000/microliter (thrombocytopenia) with evidence of HELLP
             syndrome;

          -  Persistently abnormal hepatic enzyme concentrations (twice or more upper normal
             values);

          -  Severe fetal growth restriction (ultrasound-estimated fetal weight less than fifth
             percentile);

          -  Severe Oligohydramnios (AFI &lt; 5cm)

          -  Reversal of end diastolic flow(REDF) in umbilical artery Doppler testing;

          -  New onset renal dysfunction or increasing renal dysfunction (serum creatinine &gt; 1.1
             mg/dL;

          -  Recurrent (&gt; 2 readings &gt; 30 minutes apart) severe hypertension despite
             antihypertensive therapy;

          -  Eclampsia;

          -  Pulmonary edema;

          -  Abruption placentae;

          -  Nonreassuring fetal status during daily testing (biophysical profile &lt;4/10 and/or
             recurrent variable or late decelerations);

          -  IUFD
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babbette LaMarca, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Babbette LaMarca, PhD</last_name>
    <phone>(601)815-1430</phone>
    <email>bblamarca@umc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Winfred L. Wiser Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Babbette LaMarca, PhD</last_name>
      <phone>601-815-1430</phone>
      <email>bblamarca@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Venessia Johnson, RN</last_name>
      <phone>(601)984-5328</phone>
      <email>vkjohnson@umc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 9, 2016</lastchanged_date>
  <firstreceived_date>November 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Babbette Lamarca</investigator_full_name>
    <investigator_title>Professor, Obstretrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
